Terms ending in 2039
Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,033,636 | Polypeptides Antagonizing WNT Signaling in Tumor Cells In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 12,285,493 | Polypeptides Antagonizing WNT Signaling in Tumor Cells In force · Low confidence | Boehringer Ingelheim International GmbH | In force | Low confidence | |
| US 12,753,224 | Aggrecan Binding Immunoglobulins In force · High confidence | Merck Patent GmbH | In force | High confidence | |
| US 11,813,307 | Polypeptides Binding ADAMTS5, MMP13 and Aggrecan In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 12,371,496 | T Cell Recruiting Polypeptides Based on CD3 Reactivity In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 12,209,136 | ADAMTS Binding Immunoglobulins Ablynx N.V. and Sanofi In force · Medium confidence | Ablynx N.V. and Sanofi | In force | Medium confidence | |
| US 11,999,797 | Methods of Treating Initial Episode of TTP with Immunoglobulin Single Variable Domains In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 12,480,957 | Method of Screening for Anti-Drug Antibodies Against Immunoglobulin Single Variable Domain-Based Drugs In force · High confidence | Ablynx N.V. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by Ablynx N.V..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.